News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cardio3 BioSciences Announces Secondary Placement With New Institutional Investors


7/9/2014 10:42:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Six Swiss institutional funds purchase existing shares of the Company in a secondary placement

Mont-Saint-Guibert, Belgium, - Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, today announces the addition of six Swiss institutional funds to its shareholder base.

This transaction occurred aside of the market by exchange of shares between certain historical shareholders of the Company and Swiss professional investors. The proportion of shares sold by the existing shareholders does not exceed 25% of their stake in the Company. The share capital and the number of shares of the Company remain unchanged after this secondary transaction.

Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: “We are delighted to welcome new institutional funds to our shareholders. It reinforces our institutional shareholders base and has allowed us to manage to the benefit of all our shareholders the partial exit of some historical shareholders of the Company,”

For more information contact:
Cardio3 BioSciences
www.c3bs.com
Patrick Jeanmart, CFO
Tel : +32 10 39 41 00

Anne Portzenheim, Communication Manager
aportzenheim@c3bs.com

Citigate Dewe Rogerson
Chris Gardner
Tel : +44 (0) 207 638 9571

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.
The Company’s lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient’s own cells that are harvested from the patient’s bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.
Cardio3 BioSciences has also developed C-Cath®ez, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.
Cardio3 BioSciences’ shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES